PML with dimethyl fumarate-No role for natalizumab?

被引：0
|
作者：
Berger, Joseph R. [1 ]
机构：
[1] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷 / 12期
关键词：
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; MULTIPLE-SCLEROSIS; JC VIRUS; EXPRESSION;
D O I：
10.1177/1352458519872897
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1686 / 1687
页数：2
相关论文
共 50 条
  • [21] Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation
    Zhu, C.
    Kalincik, T.
    Horakova, D.
    Zhen, Z.
    Buzzard, K.
    Skibina, O.
    Alroughani, R.
    Izquierdo, G.
    Eichau, S.
    Kuhle, J.
    Patti, F.
    Grand'Maison, F.
    Hodgkinson, S.
    Grammond, P.
    Lechner-Scott, J.
    Butler, E.
    Prat, A.
    Girard, M.
    Duquette, P.
    Macdonell, R.
    Weinstock-Guttman, B.
    Ozakbas, S.
    Slee, M.
    Sa, M. Jose
    Van Pesch, V.
    Barnett, M.
    Van Wijmeersch, B.
    Gerlach, O.
    Prevost, J.
    Terzi, M.
    Boz, C.
    Laureys, G.
    Van Hijfte, L.
    Kermode, A.
    Garber, J.
    Yamout, B.
    Khoury, S. J.
    Jokubaitis, V.
    Monif, M.
    Merlo, D.
    Van der Walt, A.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 645 - 647
  • [22] Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors
    Jonathan Zurawski
    Ashley Flinn
    Lindsay Sklover
    Jacob A. Sloane
    Journal of Neurology, 2016, 263 : 1511 - 1517
  • [23] Can dimethyl-fumarate be a good treatment choice after natalizumab discontinuation?
    Farina, G.
    Pitteri, M.
    Magliozzi, R.
    Castellaro, M.
    Camera, V.
    Romualdi, C.
    Bertoldo, A.
    Monaco, S.
    Calabrese, M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 598 - 599
  • [24] Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors
    Zurawski, Jonathan
    Flinn, Ashley
    Sklover, Lindsay
    Sloane, Jacob A.
    JOURNAL OF NEUROLOGY, 2016, 263 (08) : 1511 - 1517
  • [25] Fatal PML in a patient treated with compounded dimethyl fumarate with only modest lymphocytopenia
    Murk, J. L.
    Nieuwkamp, D. J.
    Van Hecke, W.
    Frijlink, D. W.
    Killestein, J.
    Wattjes, M. P.
    Van Oosten, B. W.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E6 - E6
  • [26] Modeling probability of cases of dimethyl fumarate-associated PML with normal lymphocytes
    Carruthers, R.
    Healy, B. C.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 292 - 292
  • [27] Stratification of PML risk with natalizumab
    Reactions Weekly, 2012, 1404 (1) : 3 - 3
  • [28] Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
    Hou, Jue
    Kim, Nicole
    Cai, Tianrun
    Dahal, Kumar
    Weiner, Howard
    Chitnis, Tanuja
    Cai, Tianxi
    Xia, Zongqi
    JAMA NETWORK OPEN, 2021, 4 (11) : E2134627
  • [29] Natalizumab and PML: a risky business?
    Clifford, David B.
    GUT, 2008, 57 (10) : 1347 - 1349
  • [30] A closer look at natalizumab, PML
    Reactions Weekly, 2010, 1303 (1) : 6 - 6
12345